- Home
- JQC vs FULC Comparison
JQC vs FULC Comparison
Compare JQC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JQC | FULC |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 718.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | JQC | FULC |
|---|---|---|
| Price | $4.76 | $7.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 823.8K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.60 | $2.32 |
| 52 Week High | $5.58 | $15.74 |
Technical Indicators
Market Signals| Indicator | JQC | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 26.33 | 33.95 |
| Support Level | N/A | $7.40 |
| Resistance Level | $5.16 | $8.50 |
| Average True Range (ATR) | 0.05 | 0.79 |
| MACD | -0.02 | -0.18 |
| Stochastic Oscillator | 8.62 | 6.43 |
Price Performance
Historical ComparisonAbout JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.